Experts discuss the transformative impact of B-cell–directed and high-efficacy disease-modifying therapies (DMTs) in managing Multiple Sclerosis, emphasizing early initiation to prevent disability while balancing safety, patient preferences, and long-term treatment considerations to optimize outcomes.
